By Liz Moyer
Hims & Hers Health, a telehealth platform that sells knock offs of popular weight loss drugs, sank in after-hours trading after missing expectations on quarterly earnings and revenue.
The stock was down 12% at $55.68 in after-hours trading Monday. It is up 162% so far this year, according to Dow Jones Market Data.
The company reported earnings of 17 cents a share and revenue of $544.8 million, which is up more than 72% from a year ago. Analysts tracked by FactSet were even more optimistic, however. The consensus revenue forecast was $551.7 million.
Hims & Hers also issued guidance that was in line with expectations. It sees third quarter revenue in a range of $570 million to $590 million a share. Its guidance for the full year 2025 hasn't changed: Revenue of $2.3 billion to $2.4 billion and earnings before interest, taxes, depreciation, and appreciation of $295 million to $335 million.
This is a developing story. Check back here for details.
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
August 04, 2025 17:21 ET (21:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。